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Malignant Hyperthermia

Kathryn Hernandez BSN, RN, CCRN, SRNA
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Overview
q
q

q

q

Pathophysiology of Malignant
Hyperthermia

The rare genetic condition of malignant hyperthermia (MH) is widely
researched by anesthesia providers.
MH is a condition in which the body goes into a hypermetabolic state
affecting skeletal muscle in response to receiving inhaled anesthetics or the
neuromuscular blocking agent, succinylcholine. Early recognition and
treatment is necessary as this condition is fatal if left untreated.
The exact incidence of MH is not well understood. MH presents in about 1 in
100,000 adult surgeries ; and 1 in about 30,000 pediatric surgeries.

q

MH research allows for a more thorough understanding of the condition: the
causes, clinical presentation, and most importantly how to treat the
condition to prevent fatalities.

q

(Malignant Hyperthermia Association of the United States, 2020; Rosenberg et al.,
2015).

q

Clinical Presentation
MH results in a hypermetabolic state causing the following signs
and symptoms:
•
Hyperthermia
- temperature rising 1-2 degrees every 5 min with temps greater than 44
degrees Celsius.
•
Tachycardia
•
Tachypnea
•
Muscle rigidity
-Occurs immediately after administration of anesthetic agent or
succinylcholine
•
Rhabdomyolysis
- Dark color urine, marked increase in CPK levels
•
Hypercapnia
- Increase in Etc02 resistant to an increase in minute ventilation
•
Hypoxia
-Follows hypercapnia
•
Acidosis
•
Hyperkalemia
-Can lead to dysrhythmias
q

Malignant Hyperthermia
Diagnostic Grading Scale

MH is an autosomal dominant disorder that is
most closely related to a mutation in the
ryanodine receptor type 1 (RyR1) gene.
•
Additional genetic mutations
associated with MH include:
CACNA1S

Treatment
q
q
•
•
q
•
•
•

Following the administration of triggering
agents such as inhaled anesthetics or
succinylcholine, the defective receptor (RyR1)
causes an uncontrolled release of calcium from
the sarcoplasmic reticulum.

Immediate discontinuation of trigger agents
Dantrolene 2.5mg/kg q 10-15 min till resolution of
symptoms
Works by directly decreasing calcium in the cell and
interferes with muscle contraction
Only drug that specifically treats MH
Supportive Care
Temperature cooling measures
Increase minute ventilation
Traditional hyperkalemia management

(Malignant Hyperthermia Association of the United States,
2020; Rosenberg et al., 2015)

Increased intracellular calcium facilitates
excessive excitation-coupling leading to
inappropriate muscle contraction and a deadly
hypermetabolic state.

(Rosenberg et al., 2015)

(Rosenberg et al., 2015; Stephens et al., 2016)

Risk Factors

q

With the complexity of this disorder and
its unique pathophysiological process it is
crucial that all parts of the surgical team,
especially anesthesia providers,
understand how to treat a patient with
MH.

q

Certified registered nurse anesthetists
(CRNA) are responsible for monitoring
patients very closely. Clinical signs of MH
must be recognized and treated early in
order to decrease morbidity and mortality.

q

Increased understanding of the clinical
manifestation and pathophysiology of MH
has led to a decrease in mortality from
80% thirty years ago to <5% in 2006.

(Rosenberg et al., 2015).
q
q
q
q
q
q

Prior history of MH
Musculoskeletal disorder
History of rhabdomyolysis
Greater incidence in males
.
Highest incidence in young people, with average age of 18.3
years
If parent has defect RyR1 gene, 50% chance of passing it to
offspring (autosomal dominant)
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Nursing Implications

Diagnosis
q

Based on clinical presentation/ lab testing:

•
•
•
•

Elevated temperature: >38.8 increasing 1 degree every 5 minutes
Elevated EtC02 >55mmHg despite increased minute ventilation
Muscle rigidity
Rhabdomyolysis: elevated creatine kinase, cola-colored urine,
elevated myoglobin
Blood/plasma/serum K+> 6 mEq/L

•
q
•

The “gold standard” for diagnosis of MH is an in vitro contracture
test.
Based on contracture of muscle fibers in the presence of
halothane or caffeine

(Rosenberg et al., 2015)
(AANA, 2020)

Conclusion &
Significance

Medical interventions:
q Administration of dantrolene
q Management of hyperkalemia such as administration of insulin/ glucose
q Manage hemodynamics
q Maintain normothermia
Assessment:
q Understand and monitor for early signs and symptoms of MH
q Assess for susceptibilities of MH and past medical history
q Collect and monitor lab results
(Norgine, 2016)

(AANA, 2020; Malignant Hyperthermia Association of the United States, 2020;
Rosenberg et al., 2015)

